PALATIN TECHNOLOGIES INC

Palatin Technologies, a biopharma firm on NYSE American, rebounds with a $11.80 stock price after a $5.61 low, driven by R&D investments targeting sexual dysfunction, heart failure, obesity, and cachexia.

Palatin Technologies: biopharma innovator tackling sexual dysfunction, heart failure, obesity—R&D focus, market rebound, and future‑growth potential.

Palatin Technologies Inc. has announced significant financial and research developments, including an expected $11.5 million financing and promising preclinical data for its glaucoma treatment, PL9588.